PHAR Pharming Group
- 10.000
- +0.312+3.22%
- 9.540
- -0.460-4.60%
Pharming Group News
Pharming Reports Q1 Results
Analysts' Top Healthcare Picks: Opko Health (OPK), Pharming Group (PHAR)
Pharming Group Boasts Strong Q1 Revenue Growth
Pharming GAAP EPS of -$0.01 Misses by $0.02, Revenue of $55.6M Misses by $14.47M
Pharming Group | 6-K: Report of foreign private issuer (related to financial reporting)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Definitive Healthcare Corp (DH), Orthofix (OFIX) and Pharming Group (OtherPHGUF)
Pharming Q1 2024 GAAP EPS $(0.02) Misses $0.01 Estimate, Sales $55.586M Miss $68.425M Estimate
Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.01 by 290 percent. This is unchanged from the same period last year. The compan
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAllarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. Emergent BioSol
Oppenheimer Remains a Buy on Pharming Group (PHAR)
Pharming Group's Strategic Financial Maneuver
Pharming Group Lauded for Rare Disease Treatment
Pharming Group to Report First Quarter 2024 Financial Results on May 8
Pharming to Be Honored as Industry Innovator at National Organization for Rare Disorders (NORD) 2024 Rare Impact Awards
Recognition given for achievement in commercializing Joenja (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April
Pharming Group to Buy Back EUR123 Million of Bonds Due 2025
Pharming Group (PHARM.AS) accepted 123.1 million euros of its outstanding 125 million euros of 3% senior unsecured convertible bonds due 2025 for repurchase. The Dutch biopharmaceutical company said A
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds
Pharming Group (PHARM.AS) on Thursday launched an offering of 100 million euros of senior unsecured convertible bonds due 2029 and a repurchase offer for its outstanding 125 million euros of convertib
Optimistic Buy Rating on Pharming Group Backed by Promising Leniolisib Trials and Strategic Market Expansion
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of Its Treatment for Rare Auto-Immune Disorder
Pharming Group (PHAR) said Monday it has finished enrolling 21 patients in a phase 3 clinical trial to evaluate leniolisib as a potential treatment for children aged four to 11 years old with activate
Reported Earlier, Pharming Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib
Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the completion of patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug lenioli
Joenja's Journey: Navigating the Market Risks and Regulatory Challenges Post-Approval for Pharming Group Nv
Pharming Group Files Annual Report, Sets AGM Date
Analysis
Price Target
No Data
